Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment

Core Viewpoint - Mesoblast Limited has provided an update on Ryoncil (remestemcel-L-rknd), the first FDA-approved mesenchymal stromal cell product for treating steroid-refractory acute graft-versus-host disease (SR-aGvHD) in children aged 2 months and older, highlighting its early survival rates and ongoing commercial efforts to expand its use [1][8]. Group 1: Clinical Outcomes - Among the first 25 patients treated with Ryoncil, 21 patients (84%) survived and completed the initial 28-day treatment regimen as per FDA approval [2] - The four patients who did not complete the treatment had previously failed other therapies and died from severe SR-aGvHD within 28 days, underscoring the importance of early intervention [2] Group 2: Patient Access and Coverage - Mesoblast has established a patient access hub, MyMesoblast™, to facilitate ordering Ryoncil, ensuring that patients can access this therapy [3] - Ryoncil is covered by government and commercial payers, reaching over 260 million U.S. lives, with specific billing codes issued by CMS enhancing its usage under federal coverage [4] Group 3: Market Expansion and Future Trials - The company aims to expand Ryoncil's FDA label to include adults with severe SR-aGvHD, targeting a market size approximately three times larger than the pediatric population [5] - A pivotal trial for Ryoncil in adults is set to commence site enrollment this quarter, in collaboration with the NIH-funded Bone Marrow Transplant Clinical Trials Network [5] Group 4: Company Overview and Technology - Mesoblast is a leader in developing allogeneic cellular medicines for severe inflammatory conditions, utilizing proprietary mesenchymal lineage cell therapy technology [7] - The company is also developing additional therapies for other inflammatory diseases and has established commercial partnerships in Japan, Europe, and China [9]